{"analyses":[{"ciLowerLimit":"-12","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Risk Difference (RD)","paramValue":"-6"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.5","upperLimit":"45.3","value":"40.8"},{"groupId":"OG001","lowerLimit":"42.4","upperLimit":"51.2","value":"46.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"507"},{"groupId":"OG001","value":"509"}],"units":"Participants"}],"description":"Grade 3 AEs are defined as events that interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating. Grade 4 AEs are defined as events that are potentially life threatening.","dispersionType":"95% Confidence Interval","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"NUMBER","populationDescription":"The safety population includes all participants with available data post baseline, analyzed as treated.","reportingStatus":"POSTED","timeFrame":"Day 1 through Day 29","title":"Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}